Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer (PFE) entered a licensing agreement with China’s Sciwind Biosciences for its type 2 diabetes treatment ecnoglutide ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Hangzhou ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased ...

"Two things at once," the Kansas City Chiefs player repeats in the ad, as he promotes getting both shots in one sitting. Travis Kelce stars in a Pfizer commercial backing both the COVID-19 and flu ...

Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in ...